

July 24, 2009

ReSearch Pharmaceutical Services, Inc.
Proposed Cancellation of Shares and Warrants from Trading on AIM

ReSearch Pharmaceutical Services, Inc. ("RPS" or the "Company"), a leading provider of clinical development outsourcing solutions to the biopharmaceutical industry, announces that it is seeking stockholders' approval for the cancellation of its common stock from trading on AIM and warrant holders' approval for the cancellation of its warrants from trading on AIM.

RPS is today mailing a proxy statement convening a Special Meeting of stockholders and warrant holders to be held at its headquarters, 520 Virginia Drive, Fort Washington, Pennsylvania 19034, at 9 a.m., local time, on August 26, 2009.

Subject to obtaining the requisite approvals from its stockholders and warrant holders, RPS presently intends to cancel its common stock and warrants from trading on AIM on or about September 4, 2009. RPS reserves the right to forego cancelling the common stock and warrants from trading on AIM if the Board of Directors determines that remaining admitted to trading on AIM is in the best interests of RPS and its stockholders and warrant holders.

If the stockholders approve the cancellation of the common stock from trading on AIM, but the warrant holders do not approve the cancellation of the warrants from trading on AIM, our nominated advisor has indicated that it will resign from its position as nominated advisor as of the date our common stock is cancelled from trading on AIM. Thereafter, trading of our warrants on AIM will be suspended, and if RPS does not appoint another nominated advisor within one month after the suspension of its warrants from trading on AIM (which appointment of a new nominated advisor RPS believes to be unlikely), the admission of the warrants to trading on AIM will be cancelled.

Additional information regarding the proposed cancellation of the Company's stock and warrants from trading on AIM can be found in the Proxy Statement being mailed to all stockholders and warrant holders today.

This announcement is a summary of the information contained in the Proxy Statement and as such should be read in conjunction with the full text of the Proxy Statement. The Proxy Statement is being filed with the United States Securities and Exchange Commission ("SEC") and is publicly available on the SEC's website (www.sec.gov). Copies of the Proxy Statement will also be available on the Company's website, www.rpsweb.com.

THIS ANNOUNCEMENT IS NOT "SOLICITING MATERIAL," IS NOT DEEMED "FILED" WITH THE SEC AND IS NOT TO BE INCORPORATED BY REFERENCE IN ANY FILING OF THE COMPANY UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, WHETHER MADE BEFORE OR AFTER THE DATE HEREOF AND IRRESPECTIVE OF ANY GENERAL INCORPORATION LANGUAGE IN ANY SUCH FILING.

For further information please contact:

ReSearch Pharmaceutical Services, Inc.:
Daniel M. Perlman, Chairman & Chief Executive Officer
Steven Bell, Chief Financial Officer

+1 215 540 0700

Nominated Adviser and UK Broker:
Arbuthnot Securities Limited
James Steel / Ed Burbidge

+44 20 7012 2000